{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:05:07Z","timestamp":1791378307155,"version":"4.3.2"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jgar.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T18:29:33Z","timestamp":1659896973000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016\u20132018)"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7732-4762","authenticated-orcid":false,"given":"Harald","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-0334","authenticated-orcid":false,"given":"Joseph","family":"Blondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Luca\u00dfen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-3069","authenticated-orcid":false,"given":"Eric A.","family":"Utt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2022.08.002_bib0002","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2022.08.002_sbref0003","series-title":"Antibiotic resistance threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.jgar.2022.08.002_bib0004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jinf.2019.09.012","article-title":"The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis","volume":"79","author":"Mohd Sazlly Lim","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2022.08.002_bib0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2019.05.017","article-title":"Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study","volume":"79","author":"Russo","year":"2019","journal-title":"J Infection"},{"key":"10.1016\/j.jgar.2022.08.002_bib0006","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1080\/22221751.2019.1698273","article-title":"The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis","volume":"8","author":"Ayobami","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jgar.2022.08.002_bib0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcimb.2017.00055","article-title":"Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options","volume":"7","author":"Lee","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jgar.2022.08.002_bib0008","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00284-019-01836-z","article-title":"Molecular surveillance of multidrug-resistant Acinetobacter baumannii","volume":"77","author":"AlAmri","year":"2020","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.jgar.2022.08.002_bib0009","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","article-title":"Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment","volume":"25","author":"Piperaki","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2022.08.002_bib0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical analysis of antibacterial agents in clinical development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2022.08.002_sbref0011","series-title":"TYGACIL U.S. Physician Prescribing Information","year":"2020"},{"key":"10.1016\/j.jgar.2022.08.002_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-015-0085-1","article-title":"Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013","volume":"14","author":"Hoban","year":"2015","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2022.08.002_bib0013","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijantimicag.2018.07.003","article-title":"In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study","volume":"52","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.08.002_bib0014","unstructured":"ATLAS (Antimicrobial Testing Leadership and Surveillance). Pfizer. https:\/\/atlas-surveillance.com. Accessed 17 March 2021."},{"key":"10.1016\/j.jgar.2022.08.002_bib0015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2015"},{"key":"10.1016\/j.jgar.2022.08.002_bib0016","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. http:\/\/www.eucast.org. Accessed 19 May 2021."},{"key":"10.1016\/j.jgar.2022.08.002_bib0017","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.diagmicrobio.2017.08.014","article-title":"Antimicrobial activity among gram-positive and gram-negative organisms collected from the Asia-Pacific region as part of the Tigecycline Evaluation and Surveillance Trial: comparison of 2015 results with previous years","volume":"89","author":"Yang","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2022.08.002_bib0018","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12941-017-0222-0","article-title":"Antimicrobial susceptibility among gram-positive and gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial","volume":"16","author":"Vega","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2022.08.002_bib0019","doi-asserted-by":"crossref","first-page":"e02534","DOI":"10.1128\/AAC.02534-19","article-title":"In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016 and 2017","volume":"64","author":"McLeod","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.08.002_bib0020","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.cmi.2022.02.024","article-title":"How to: ECOFFs \u2013 the why, the how, and the don\u2019ts of EUCAST epidemiological cutoff values","volume":"28","author":"Kahlmeter","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2022.08.002_bib0021","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). MIC and zone diameter distributions and ECOFFs. https:\/\/www.eucast.org\/mic_distributions_and_ecoffs\/. Accessed 14 June 2022."},{"key":"10.1016\/j.jgar.2022.08.002_bib0022","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1469-0691.2006.01578.x","article-title":"EUCAST technical note on tigecycline","volume":"12","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2022.08.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.10.010","article-title":"In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii","volume":"55","author":"Seifert","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.08.002_bib0024","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jac\/dkab079","article-title":"Prevalence of RND efflux pump regulator variants associated with tigecycline resistance in carbapenem-resistant Acinetobacter baumannii from a worldwide survey","volume":"76","author":"Luca\u00dfen","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.002_bib0025","doi-asserted-by":"crossref","first-page":"e01326","DOI":"10.1128\/AAC.01326-19","article-title":"Novel plasmid-mediated tet(X5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical Acinetobacter baumannii isolate","volume":"64","author":"Wang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.08.002_bib0026","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jac\/dkaa037","article-title":"Identification of the novel tigecycline resistance gene tet(X6) and its variants in Myroides, Acinetobacter and Proteus of food animal origin","volume":"75","author":"Liu","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.002_bib0027","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2022.08.002_bib0028","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/jac\/dkaa370","article-title":"In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms","volume":"75","author":"Trebosc","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.002_bib0029","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2022.08.002_bib0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2022.08.002_bib0031","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/AAC.48.5.1586-1592.2004","article-title":"In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains","volume":"48","author":"Higgins","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:45Z","timestamp":1761991185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522001928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":31,"alternative-id":["S2213716522001928"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.08.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016\u20132018)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Pfizer Inc and The Author(s). Published by Elsevier Ltd. On behalf of International Society for Chemotherapy of Infection and Cancer","name":"copyright","label":"Copyright"}]}}